胃癌前病变亚型的患病率与进展率:系统综述与荟萃分析
结果显示不完全型IM进展率显著高于完全型IM,高级别异型增生(HGD)进展率显著高于低级别异型增生(LGD),支持按亚型进行风险分层。
要点
- 不完全型IM进展率显著高于完全型IM(12.15 vs 1.73/1000人年,P<.01)。
- HGD进展率显著高于LGD(344.48 vs 11.55/1000人年,P<.01)。
- 局限型与广泛型IM进展率无显著差异(P=.80),亚型分型在临床中应用不足。
核心结论
- 不完全型IM和HGD等高进展风险亚型占癌前病变总负担的较大比例,但亚型分型在临床实践中仍未充分利用。
- 尽管估计值受异质性限制,病变亚型间进展率差异支持在管理指南中对这些病变进行风险分层,尤其完全型与不完全型IM、LGD与HGD。
研究设计与样本
- 系统综述与荟萃分析,检索数据库纳入报告内镜下IM和异型增生亚型患病率与进展率的出版物,包括完全型/不完全型IM、局限型(仅胃窦)/广泛型(累及胃体)IM、LGD和HGD。
主要发现
- 完全型IM患病率为11%(95%CI 8%-15%),不完全型IM为10%(95%CI 6%-14%),对应进展率分别为1.73(95%CI 1.08-2.79)和12.15(95%CI 5.28-27.94)/1000人年(P<.01)。
- 局限型IM患病率为12%(95%CI 8%-17%),广泛型IM为5%(95%CI 4%-8%),对应进展率分别为3.31(95%CI 1.18-9.32)和4.19(95%CI 0.95-18.41)/1000人年(P=.80)。
- LGD患病率为2%(95%CI 1%-4%),HGD为0.28%(95%CI 0.14%-0.55%),对应进展率分别为11.55(95%CI 5.93-22.47)和344.48(95%CI 144.88-819.09)/1000人年(P<.01)。
- 所有估计值均观察到显著异质性。
关键数值与推荐
- 不完全型IM进展率12.15/1000人年(95%CI 5.28-27.94),完全型IM为1.73/1000人年(95%CI 1.08-2.79),P<.01。
- HGD进展率344.48/1000人年(95%CI 144.88-819.09),LGD为11.55/1000人年(95%CI 5.93-22.47),P<.01。
- 局限型IM进展率3.31/1000人年(95%CI 1.18-9.32),广泛型IM为4.19/1000人年(95%CI 0.95-18.41),P=.80。
临床怎么用
- 对胃黏膜肠上皮化生应进行亚型分型(完全型vs不完全型),不完全型IM进展风险更高,可考虑更密切随访。
- 异型增生应区分LGD与HGD,HGD进展风险极高,需积极干预或密切监测。
- 局限型与广泛型IM进展率无显著差异,但广泛型IM患病率较低,临床可结合其他风险因素综合管理。
局限性
- 所有估计值均存在显著异质性。
- 研究间异质性限制了估计值的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Gastric intestinal metaplasia (IM) and dysplasia are precursor lesions for gastric cancer. This systematic review and meta-analysis examined the global prevalence and progression rates of subtypes of these understudied lesions. METHODS: We searched databases for publications reporting prevalence and progression of subtypes of IM and dysplasia among individuals undergoing endoscopy, including incomplete/complete IM, limited (antrum-restricted)/extensive (corpus-involving) IM, and low-grade dysplasia (LGD) and high-grade dysplasia (HGD). Random-effects models were used to estimate pooled prevalence and progression rates to gastric cancer. The I2 statistic was used to determine heterogeneity. RESULTS: Eighty-three studies were included for prevalence and 23 for progression. The prevalence of complete IM was 11% (95% confidence interval [CI], 8%-15%) and of incomplete IM was 10% (95% CI, 6%-14%), with corresponding progression rates of 1.73 (95% CI, 1.08-2.79) vs 12.15 (95% CI, 5.28-27.94) per 1000 person-years, respectively (P < .01). The prevalence of limited vs extensive IM was 12% (95% CI, 8%-17%) vs 5% (95% CI, 4%-8%), respectively, and the corresponding progression rates were 3.31 (95% CI, 1.18-9.32) vs 4.19 (95% CI, 0.95-18.41) per 1000 person-years (P = .80). The prevalence of LGD was 2% (95% CI, 1%-4%) and of HGD was 0.28% (95% CI, 0.14%-0.55%), with corresponding progression rates of 11.55 (95% CI, 5.93-22.47) vs 344.48 (95% CI, 144.88-819.09; P < .01). Substantial heterogeneity was observed for all estimates. CONCLUSIONS: Although lesion subtypes with high progression risk like incomplete IM account for a large portion of the total burden of precancerous lesions, subtyping remains underutilized in clinical practice. Although estimates are limited by heterogeneity, differences in progression rates between lesion subtypes support risk stratification of these lesions within management guidelines, particularly complete vs incomplete IM and LGD vs HGD.
引用
- Grell Y, Mülder DT, Hahn AI, et al. Prevalence and Progression of Subtypes of Gastric Premalignant Lesions: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 42680048. doi:10.1016/j.cgh.2026.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。